PADI4 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-PADI4 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPADI4
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatantigen affinity purified
Size0.02 mL, 0.06 mL, 0.12 mL
Concentration0.6mg/mL
ApplicationsWestern Blot (WB), Immunohistochemistry (IHC), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis gene is a member of a gene family which encodes enzymes responsible for the conversion of arginine residues to citrulline residues. This gene may play a role in granulocyte and macrophage development leading to inflammation and immune response. PADI4 plays a role in the epigenetics, the deimination of arginines on histones 3 and 4 can act antagonistically to arginine methylation. The protein may be found in oligomers and binds 5 calcium ions per subunit. It catalyses the reaction: Protein L-arginine + H2O = protein L-citrulline + NH3.
ImmunogenImmunogen: Fusion protein of human PADI4
Other Names[EC 3.5.3.15; HL 60 PAD; HL-60 PAD; PAD 4; PAD; PADI 4; PADI 5; PADI H protein; Padi4; PADI4; PADI5; PDI 4; PDI 5; PDI4; PDI5; Peptidyl arginine deiminase type IV; Peptidyl arginine deiminase type V; Peptidylarginine deiminase IV; Protein arginine deiminase; Protein arginine deiminase type 4; Protein arginine deiminase type IV; Protein-arginine deiminase type IV; Protein-arginine deiminase type-4]
Gene, Accession #[PADI4], Gene ID: 23569, NCBI: Q9UM07.2, UniProt: Q9UM07
Catalog #MBS2562066
Price$110, $150, $225
Order / More InfoPADI4 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.